One of these trials focuses on the number of adverse events as the primary outcome of cryoablation, Nivolumab (anti-PD-L1), and Ipilimumab (anti-CTLA-4) treatment in patients with early-stage breast cancer [42]. Here, CTLA4 is linked to breast cancer.